Dr. Barbui on Hematocrit Levels in Polycythemia Vera

Tiziano Barbui, MD
Published: Sunday, Dec 09, 2012

Tiziano Barbui, MD, USC Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy, on hematocrit (HCT) levels in patients with polycythemia vera (PV).

Due to varying results in two large randomized clinical trials (PVSG-1 and ECLAP), clinical oncologists are uncertain of the HCT levels in patients with PV.

A large scale randomized clinical trial was designed to determine the efficacy and safety of HCT levels to prevent thrombotic events in PV. The trial specifically compared the recommended HCT target compared to HCT levels between 0.45 and 0.50. Patients were randomized to two groups: HCT <0.45 and HCT 0.45-0.50. The incidence of major cardiovascular events was four times as high in patients with HCT levels >0.45. The research concluded that HCT level <0.45 is statistically significant to prevent thrombotic complications and the target of therapy in patients with PV.

<<< View coverage from the 2012 ASH Meeting

Tiziano Barbui, MD, USC Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy, on hematocrit (HCT) levels in patients with polycythemia vera (PV).

Due to varying results in two large randomized clinical trials (PVSG-1 and ECLAP), clinical oncologists are uncertain of the HCT levels in patients with PV.

A large scale randomized clinical trial was designed to determine the efficacy and safety of HCT levels to prevent thrombotic events in PV. The trial specifically compared the recommended HCT target compared to HCT levels between 0.45 and 0.50. Patients were randomized to two groups: HCT <0.45 and HCT 0.45-0.50. The incidence of major cardiovascular events was four times as high in patients with HCT levels >0.45. The research concluded that HCT level <0.45 is statistically significant to prevent thrombotic complications and the target of therapy in patients with PV.

<<< View coverage from the 2012 ASH Meeting


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x